Ed Esplin: Real-World Evidence Supports Shift to Universal Genetic Testing in Breast Cancer Care
Ed Esplin, Clinical Geneticist and Medical Officer of Invitae, shared a post on X about a paper he co-authored with colleagues, published in JAMA Network Open:
“Our study provides RWE that universal genetic testing, per the American Society of Breast Surgeons (ASBrS), can identify patients with actionable PGMs who are missed under the currently published NCCN criteria…
Highlights the utility of a universal testing approach in breast cancer care… supports a shift from selective to universal (germline testing) in oncology – a transition that mirrors broader trends in precision medicine.”
Title: Clinical Utility of Universal Germline Genetic Testing for Patients With Breast Cancer
Authors: Pat W. Whitworth, Peter D. Beitsch, Rakesh Patel, Barry Rosen, Gia Compagnoni, Paul L. Baron, Rache Simmons, Eric A. Brown, Linsey Gold, Dennis Holmes, Linda Ann Smith, Michael Kinney, Ian Grady, Patricia Clark, Karen Barbosa, Samuel Lyons, Lee Riley, Cynara Coomer, Lisa Curcio, Antonio Ruiz, Sadia Khan, Heather MacDonald, Kevin Hughes, Mary Kay Hardwick, Brandie Heald, Sandra B. Munro, Sarah M. Nielsen, Edward D. Esplin
You can read the Full Article on JAMA Network Open.
You also read:
“Underdiagnosis of Hereditary Breast Cancer: Are Genetic Testing Guidelines a Tool or an Obstacle?”
More posts featuring Ed Esplin.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023